Novartis is paying $925 million upfront to acquire Anthos Therapeutics, whose launch the pharma backed in February 2019.

The acquisition of Anthos Therapeutics could be worth up to $3.1 billion and returns to Novartis a blood thinner it licensed to the Blackstone-backed startup six years ago.

Novartis AG agreed to buy US biotech Anthos Therapeutics for as much as $3.1 billion to gain a preventative stroke medicine that could be the first of its kind.

The Business Research Company Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

Novo Nordisk today announced interim results from the phase 3 FRONTIER3 trial of 70 children (aged 1-11 years old) with haemophilia A with and without inhibitors. The trial initially assessed ...

Long-term exposure to certain air pollutants significantly increased risk for venous thromboembolism, according to results of ...

Thurner syndrome (MTS) is a clinicopathological condition where the left common iliac vein is compressed by the overlying right common iliac artery, potentially leading to deep vein thrombosis (DVT) ...

In the 1960s, an obscure Scandinavian researcher identified a peculiar blood fat particle that became known as lipoprotein(a) ...

Gene therapy using modified blood stem cells helped five adults with severe hemophilia A reach therapeutic levels of clotting ...

There are various reasons for the disparity, but one important factor is outsized stock ownership among the richest Americans. The 1% own more than 50% of the equity shares in both private and ...

Researchers evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors for ... in cardiovascular disease." About 1-in-3 people will develop atrial fibrillation ...

Researchers from Mass General Brigham evaluated a drug that represents a new class of anticoagulants known as Factor XI inhibitors ... disease.” About 1-in-3 people will develop atrial ...